We revealed that patients with high WAS expression were less sensitive to immunotherapy medications.<h4>Conclusion</h4>In conclusion, our study identified that WAS was a prognostic biomarker and correlated with immune infiltrates in ccRCC. Here, WAS is linked to nonpapillary renal cell carcinoma.